Apricus Biosciences' CEO Sees Higher Revenue if Pfizer Viagra Litigation is Successful

Dr. Bassam Damaj, the Chairman, President and Chief Executive Officer of Apricus Biosciences, Inc. APRI noted today his belief that the specialty biopharmaceutical company could see higher revenues should Pfizer, Inc. PFE be successful in its patent litigation battle against the introduction of generic versions of its Viagra product for the treatment of erectile dysfunction. "If the recent global litigation effort by Pfizer is successful in extending the life of its Viagra® patents in certain markets, then Apricus Bio and its partners could expect to see the projected per unit price of its Vitaros® product for ED increase an average of $1.00 to $2.00 over the next several years in those geographic areas," said Dr. Damaj. "This could result in higher projected revenues for our product in the future in those markets where Pfizer is successful."